The global peptide therapeutics market was valued at USD 40.01 billion in 2021. It is projected to reach USD 69.93 billion by 2030, growing at a CAGR of 6.4% during the forecast period (2022–2030).
Researchers have employed peptides' tiny size and versatility to treat various chronic diseases, including cancer. Due to their remarkable efficacy and selectivity towards the distinct receptors on target cells, researchers have used peptides to deliver drugs to target cells. Several peptide therapies have already been given market authorization and are approved to treat various illnesses. Increasing cancer and metabolic disorders increased investments in research and development of innovative medications, and technological improvements in peptide therapies are the primary drivers of the global peptide therapeutics market.
Researchers have recently created several peptide-based anticancer vaccines capable of inducing cancer-specific immune responses in different tests for diverse cancer types. However, clinical responses have thus far been limited to a single patient, and broad clinical application has not yet been attained. Therefore, additional efforts are required to enhance peptide vaccination to incorporate this medication with minimal side effects into the clinical practice for cancer treatment. Currently, GV1001 is the only peptide-based vaccination licensed for treating pancreatic cancer in South Korea.
|Market Size||USD 69.93 billion by 2030|
|Fastest Growing Market||Asia Pacific|
|Largest Market||North America|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
The increased incidence of cancer and metabolic illnesses such as osteoporosis, obesity, and diabetes will boost the adoption of peptide therapies. Due to the increasing number of affected pediatric children and the prevalence of target diseases in low-income countries, there is a strong demand for effective and cost-effective medications. Advanced peptides are currently being produced and modified as COVID-19 treatments. In order to treat the complications brought on by infection, researchers are looking for substances that inhibit the mechanisms involved in severe acute respiratory infection and replication. These factors are increasing the demand for the peptide therapeutics market.
Technology advancements have reduced the overall costs of producing therapeutic peptides, which has incentivized suppliers and manufacturers to look for newer methods of producing therapeutic peptides and to work with longer and more complex chains of peptides. In addition, the reduction in total costs associated with the production of therapeutic peptides has increased the production of therapeutic peptides. The growing usage of hybrid technologies to reach their economies of scale is anticipated to boost the expansion of the global peptide therapeutics market. Peptide treatments offer higher efficacy and fewer adverse side effects than conventional pharmaceutics. This contributes to an increase in patients and prescribers adopting peptide therapies.
Discovering and developing new treatments is expensive and time-consuming, delaying the eventual commercialization. Thus a significant number of the drugs are on the verge of losing their market exclusivity during the forecast. There is a possibility that the valuation and expansion of the worldwide peptide therapeutics market will be hampered by the availability of biosimilar or generic peptide therapeutic medications, as well as the expected launch of more drugs during the forecast period. The global market for peptide therapies may be impacted by initiatives by governing bodies and regulatory agencies to increase the availability of generic and biosimilar drugs because of their lower prices.
Due to numerous firms' efforts to investigate the creation of new drug candidates is anticipated that the market will experience lucrative growth throughout the forecast period. Businesses invest heavily in R&D to create novel pharmaceuticals more effectively treating their target illnesses to maintain their market position. For Example, In January 2022, Amgen and Generate Biomedicines announced a research agreement to explore and develop protein therapies for Amgen's five clinical objectives across numerous therapeutic areas and administration modalities. According to the World Health Organization, chronic diseases such as cancer, diabetes, and cardiovascular disease are the leading causes of morbidity and mortality worldwide (WHO). The prevalence of chronic diseases has increased globally, affecting people from all socioeconomic backgrounds. The market is anticipated to be driven by the rising incidence of chronic diseases, which increases the demand for efficient medications.
The global peptide therapeutics market is segmented into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.
North America is the most significant shareholder in the global peptide therapeutics market due to the rise in awareness of peptide therapy products, the increase in demand for diagnostics in cancer and other disorders, and the expansion of the biotechnology industry. In addition, increased government spending on R&D is anticipated to support peptide therapies in maintaining their dominance during the forecast period.
In the United States, there will be about 1.9 million new cases of cancer by the end of 2022, according to the American Cancer Society. This information suggests that peptides will become more well-known and progress through clinical trials in the U.S. healthcare sector. Moreover, as cancer becomes more prevalent, the demand for peptide treatment methods is anticipated to increase. Asia-Pacific region is predicted to have considerable growth over the projection period due to low raw material costs, an expanding number of businesses providing outsourcing services, a booming biotechnology sector, and increased R&D spending.
The global peptide therapeutics market is segmented by application, type, type of manufacturer, route of administration, and synthesis technology.
Based on application, the market is divided into cancer, metabolic, cardiovascular disorder, respiratory, GIT, anti-infection, pain, dermatology, CNS, and renal.
The metabolic segment dominates the global peptide therapeutics market due to growing sedentarism, terrible eating habits, and excessive alcohol consumption. Rising cancer prevalence worldwide and increased prescription of peptide therapies for cancer therapy are the major contributors to the expansion of this market segment. The rise in demand for effective and quick-acting pharmaceuticals is fueling the demand. In addition, growing awareness among healthcare providers and patients regarding the adverse effects of chemotherapy and radiation therapy is a significant element in developing alternative medicines such as peptide-based drugs.
Based on product, the market is divided into generic and innovative.
The generic segment is anticipated to increase quickly during the forecast period. It is anticipated that rising healthcare costs and more lavish federal spending on healthcare will drive generic medicine adoption. It is also considered that the expiration of patents on numerous branded pharmaceuticals is a significant driver pushing the generic category.
Based on the type of manufacturer, the market is divided into in-house and outsourced.
The category of in-house manufacturing held the most significant revenue share due to rigorous regulations, high costs associated with outsourcing, and significant players' growing involvement in developing peptide therapies in-house. Giant pharmaceutical corporations favor in-house manufacturing because they have the infrastructure and technologies necessary for large-scale production. It is anticipated that manufacturing outsourcing will rise due to challenges in producing medicines to high-quality standards. Businesses are outsourcing the Active Pharmaceutical Ingredient (API) to companies with cutting-edge technology and expertise in producing different types of peptides. In addition, growing R&D spending and capital investments by key competitors through the formation of strategic alliances are predicted to contribute to market expansion during the forecast period.
Based on the route of administration, the market is divided into parenteral, oral, pulmonary, and mucosal.
The parenteral administration dominates the market due to the high acceptance rate, faster medicine delivery, and simple application. Biopharmaceutical behemoths are continually investigating new peptide-relevant medication delivery techniques. The effectiveness of novel drug delivery technologies utilizing engineered molecules with advanced PEGylation is currently being assessed to increase drug delivery performance and patient compliance through better modes of drug distribution. Significant benefits of the oral route of medication administration include patient compliance and acceptability. The pulmonary route is recognized for the administration of peptides and proteins due to the physiological properties of the respiratory system. However, limited bioavailability and compounds with a low molecular weight that passes alveolar epithelium and inflammation are significant utilization hurdles.
Based on synthesis technology, the market is divided into Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), and Hybrid Technology.
The LPPS segment is the most dominant due to the increasing need for pure peptides to develop effective medicines. However, increased time consumption alters customer preferences toward speedier and more effective solutions such as SPPS. Solid Phase Peptide Synthesis reduces synthesis time and is utilized in various manufacturing processes. In addition, greater efficiency during synthesizing longer peptides is another market driver. The market is mainly driven by automation, scalability, and improved control over the physicochemical properties of peptides during the forecast period. As a result of advantages such as compatibility with both liquid-phase synthesis and solid-phase synthesis, hybrid technology is predicted to experience lucrative expansion. An acceptance rate is anticipated to result in a lucrative CAGR of 8.1% for hybrid technology during the projection period.